Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial-Reference-Cited by-同舟云学术

Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial

Published:2017-02-07 Issue:5 Volume:109 Page:
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Allen Carl E.¹,Laetsch Theodore W.¹,Mody Rajen¹,Irwin Meredith S.¹,Lim Megan S.¹,Adamson Peter C.¹,Seibel Nita L.¹,Parsons D. Williams¹,Cho Y. Jae¹,Janeway Katherine¹,

Affiliation:

1. Affiliations of authors: Texas Children’s Cancer Center, Texas Children’s Hospital, Houston, TX (CEA, DWP); Division of Pediatric Hematology-Oncology, Department of Pediatrics (CEA, DWP), Department of Molecular and Human Genetics (DWP), and Human Genome Sequencing Center (DWP), Baylor College of Medicine, Houston, TX; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern

Funder

National Cancer Institute

NCI National Clinical Trials Network

Pediatric NCI Molecular Analysis for Therapeutic Choice Trial

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/109/5/djw274/25422352/djw274.pdf

Reference139 articles.

1. Recurrent BRAF mutations in Langerhans cell histiocytosis;Badalian-Very;Blood,2010

2. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth;Mody;JAMA.,2015

3. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma;Perry;Proc Natl Acad Sci U S A,2014

4. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations;Pugh;Nature.,2012

5. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models;Taylor;J Clin Invest.,2009

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision oncology across the ages: Impact on children, adolescents, and young adults;Cancer Cell;2024-09

2. Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer;Journal of Clinical Oncology;2024-07-20

3. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer;Nature Communications;2024-07-11

4. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial;JCO Precision Oncology;2024-06

5. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial;The Oncologist;2024-05-30